Table 1.
Demographic and clinical characteristics
| Characteristic | N = 36 |
|---|---|
| Age, median (range), years | 41 (19-70) |
| Sex, n (%) | |
| Male | 19 (53) |
| Female | 17 (47) |
| Race, n (%) | |
| White | 20 (56) |
| Asian | 12 (33) |
| Other | 4 (11) |
| ECOG performance status, n (%) | |
| 0 | 14 (39) |
| 1 | 17 (47) |
| 2 | 5 (14) |
| Disease status at enrollment, n (%) | |
| Locally advanced | 7 (19) |
| Metastatic | 29 (81) |
| Years since initial diagnosis, median (range) | 1.1 (0.0-13.0) |
| NTRK gene fusion, n (%) | |
| NTRK1 | 19 (53) |
| NTRK2 | 1 (3) |
| NTRK3 | 16 (44) |
| Subtype, n (%) | |
| Bone sarcoma | |
| Chondrosarcoma | 1 (3) |
| NOS | 1 (3) |
| Gastrointestinal stromal tumors | 4 (11) |
| Soft tissue sarcoma | |
| NOS | 8 (22) |
| Malignant peripheral nerve sheath tumor | 6 (17) |
| Spindle cell sarcoma | 4 (11) |
| Epithelioid spindle sarcoma | 3 (8) |
| Inflammatory myofibroblastic tumor | 2 (6) |
| Myopericytoma | 2 (6) |
| Stromal tumor | 2 (6) |
| Dedifferentiated liposarcoma | 1 (3) |
| Fibrosarcoma | 1 (3) |
| Synovial sarcoma | 1 (3) |
| Prior therapies, n (%)a | |
| Surgery | 31 (86) |
| Radiotherapy | 21 (58) |
| Systemic therapy | 25 (69) |
| Number of prior systemic therapies, n (%) | |
| 0 | 10 (28) |
| 1 | 12 (33)b |
| 2 | 7 (19) |
| ≥3 | 7 (19) |
| Best response to prior therapy, n (%) | |
| Complete response | 1 (4) |
| Stable disease | 5 (20) |
| Progressive disease | 7 (28) |
| Otherc | 11 (44) |
ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; NTRK, neurotrophic tyrosine receptor kinase.
a
Patients may have received more than 1 type of prior therapy.
b
One patient who reported “No” to prior systemic therapies had the number of prior systemic therapies actually reported as “1”.
c
Other includes unknown and not evaluable.